摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-N-(3-chlorobenzyl)-6-(3,5-dimethylisoxazol-4-yl)quinazolin-4-amine

中文名称
——
中文别名
——
英文名称
2-chloro-N-(3-chlorobenzyl)-6-(3,5-dimethylisoxazol-4-yl)quinazolin-4-amine
英文别名
2-chloro-N-[(3-chlorophenyl)methyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)quinazolin-4-amine
2-chloro-N-(3-chlorobenzyl)-6-(3,5-dimethylisoxazol-4-yl)quinazolin-4-amine化学式
CAS
——
化学式
C20H16Cl2N4O
mdl
——
分子量
399.279
InChiKey
KYOJXQKZYJQUBC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.15
  • 拓扑面积:
    63.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Small molecule BET bromodomain inhibitors and uses thereof
    申请人:ConverGene LLC
    公开号:US11028079B2
    公开(公告)日:2021-06-08
    The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.
    本发明涉及与含结构域蛋白质结合或以其他方式调节其活性的化合物、制备这些化合物的工艺、含有这些化合物的药物组合物,以及使用这些化合物治疗各种病症和疾病的方法。
  • Discovery and lead identification of quinazoline-based BRD4 inhibitors
    作者:Shyh-Ming Yang、Daniel J. Urban、Makoto Yoshioka、Jeffrey W. Strovel、Steven Fletcher、Amy Q. Wang、Xin Xu、Pranav Shah、Xin Hu、Matthew D. Hall、Ajit Jadhav、David J. Maloney
    DOI:10.1016/j.bmcl.2018.08.039
    日期:2018.11
    A new series of quinazoline-based analogs as potent bromodomain-containing protein 4 (BRD4) inhibitors is described. The structure-activity relationships on 2- and 4-position of quinazoline ring, and the substitution at 6-position that mimic the acetylated lysine are discussed. A co-crystallized structure of 48 (CN750) with BRD4 (BD1) including key inhibitor-protein interactions is also highlighted. Together with preliminary rodent pharmacokinetic results, a new lead (65, CN427) is identified which is suitable for further lead optimization.
  • BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF
    申请人:CONVERGENE LLC
    公开号:EP3380469A1
    公开(公告)日:2018-10-03
  • SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF
    申请人:ConverGene LLC
    公开号:US20200223836A1
    公开(公告)日:2020-07-16
    The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders.
查看更多